[go: up one dir, main page]

AR039165A1 - Venlafaxina base - Google Patents

Venlafaxina base

Info

Publication number
AR039165A1
AR039165A1 ARP030101073A ARP030101073A AR039165A1 AR 039165 A1 AR039165 A1 AR 039165A1 AR P030101073 A ARP030101073 A AR P030101073A AR P030101073 A ARP030101073 A AR P030101073A AR 039165 A1 AR039165 A1 AR 039165A1
Authority
AR
Argentina
Prior art keywords
venlafaxine
base
racemic
solution
crystalline
Prior art date
Application number
ARP030101073A
Other languages
English (en)
Inventor
Rolf Keltjens
Frantisek Picha
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR039165A1 publication Critical patent/AR039165A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se refiere a una venlafaxina base racémica cristalina en donde dicha venlafaxina está en forma de partículas que tienen un tamano de partícula promedio dentro del rango de 0,5 a 200 micrones, a un procedimiento para preparar venlafaxina base racémica sólida, que comprende precipitar venlafaxina base racémica a partir de una solución de venlafaxina para formar venlafaxina base racémica cristalina; en donde dicha precipitación es llevada a cabo de acuerdo con la menos una de las siguientes condiciones: (i) dicha solución contiene una combinación de solventes que comprende al menos un solvente polar orgánico y al menos un contrasolvente seleccionado de entre agua, un hidrocarburo alifático y un hidrocarburo alicíclico; o (ii) está presente un cristal de siembra de venlafaxina base.
ARP030101073A 2002-03-28 2003-03-27 Venlafaxina base AR039165A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36773602P 2002-03-28 2002-03-28

Publications (1)

Publication Number Publication Date
AR039165A1 true AR039165A1 (es) 2005-02-09

Family

ID=28675392

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030101074A AR039166A1 (es) 2002-03-28 2003-03-27 Composiciones de venlafaxina base
ARP030101073A AR039165A1 (es) 2002-03-28 2003-03-27 Venlafaxina base

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030101074A AR039166A1 (es) 2002-03-28 2003-03-27 Composiciones de venlafaxina base

Country Status (5)

Country Link
US (2) US20030191347A1 (es)
EP (1) EP1487429A2 (es)
AR (2) AR039166A1 (es)
AU (2) AU2003226748A1 (es)
WO (2) WO2003082262A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246132A1 (en) * 2003-02-07 2006-11-02 Fjalar Johannsson Sustained release formulations of venlafaxine
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
NZ548504A (en) * 2004-02-04 2009-03-31 Alembic Ltd Extended release coated microtablets of venlafaxine hydrochloride
AU2005212166A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof
AU2005209948B2 (en) 2004-02-06 2009-09-10 Pharmatel (R&D) Pty Limited Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome
WO2005112901A1 (en) * 2004-05-21 2005-12-01 Lupin Ltd. Novel extended release composition of venlafaxine hydrochloride containing polyvinyl acetate
DE602005022175D1 (de) * 2004-05-28 2010-08-19 Salix Pharmaceuticals Inc Prävention, behandlung und linderung strahlungsinduzierter enteritis
CN1955159B (zh) 2005-06-17 2010-11-24 山东绿叶制药有限公司 用于阻断5-羟色胺以及去甲基肾上腺素再摄取的化合物,其制备方法及其用途
RU2007148195A (ru) * 2005-07-15 2009-08-20 Вайет (Us) Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102212014B (zh) * 2010-04-09 2013-12-25 江苏豪森医药集团有限公司 O-去甲基-文拉法辛的谷氨酸盐的晶型、其制备方法及其在医药上的应用
CA2788526A1 (en) * 2010-05-14 2011-11-17 Alembic Limited Extended release formulations of desvenlafaxine base
MY160607A (en) 2010-10-01 2017-03-15 Shan Dong Luye Pharm Co Ltd Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl) ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8902209D0 (en) * 1989-02-01 1989-03-22 Wyeth John And Brother Limited Preparation of cyclohexanol derivatives and novel thioamide intermediates
ES2273764T3 (es) * 1993-06-28 2007-05-16 Wyeth Nuevos tratamientos que utilizan derivados de fenetilamina.
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
PL365895A1 (en) * 2000-10-19 2005-01-10 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante

Also Published As

Publication number Publication date
WO2003082806A1 (en) 2003-10-09
US20030190352A1 (en) 2003-10-09
WO2003082262A2 (en) 2003-10-09
WO2003082262A3 (en) 2004-07-29
EP1487429A2 (en) 2004-12-22
AU2003226748A8 (en) 2003-10-13
AU2003226748A1 (en) 2003-10-13
AR039166A1 (es) 2005-02-09
US20030191347A1 (en) 2003-10-09
AU2003226752A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
AR039165A1 (es) Venlafaxina base
CO5560540A2 (es) Composicion cristalina que contiene escitalopram
CN103497762B (zh) 基于一步单组分水热合成氮掺杂碳量子点的方法
CO5670354A2 (es) Proceso para la elaboracion de aripiprazol esteril de tamaño particula promedio deseado
RU2008114306A (ru) Способ получения лекарственной композиции, основанный на увеличении сродства поверхностей кристаллических микрочастиц к активным агентам
BR0307330A (pt) Produção do delta-9-tetraidrocanabinol
ES2520841T3 (es) Procedimiento para la producción de partículas
RU2009126138A (ru) Хирургический нож, лезвие для хирургического ножа и способ их изготовления, а также рукоятка для хирургического ножа
ATE512153T1 (de) Salz einer sulfonsäure mit clopidogrel und dessen verwendung zur herstellung pharmazeutischer formulierungen
AR103711A2 (es) Procedimiento para modificar formación de cristal de fármaco, cristales modificados y composiciones que los contienen
BR0304937B1 (pt) composição de antiespumante de silicone encapsulado e processo para a produção de uma composição de antiespumante de silicone encapsulado.
NI201000234A (es) Una nueva sal de glicinato de metformina para el control de la glucosa en sangre.
AR074894A1 (es) Procedimiento para purificar un alcohol a partir de un caldo de fermentacion usando un evaporador de pelicula descendente , de pelicula agitada o de corto recorrido
AR039097A1 (es) Procedimiento y planta para la concentracion y cristalizacion evaporativa de un liquido acuoso viscoso que contiene lactosa
AR082581A2 (es) Procedimientos de preparacion de combretastatinas
GT200500257AA (es) Procedimiento para producir derivados de amina opticamente activos
CN103351309B (zh) 一种柳酰胺类防污剂及其制备方法
Zhong et al. On the origin of amorphous cores in biomimetic CaCO3 spherulites: new insights into spherulitic crystallization
ATE371464T1 (de) Flüssige zubereitung für kontaktlinsen
PE20061014A1 (es) Clorhidrato de lercanidipina amorfo
RU2007100884A (ru) Способ получения регулярных систем наноразмерных нитевидных кристаллов кремния
BR0312604A (pt) ácidos imido-alcanpercarboxìlicos, composições, e, processo para a preparação e uso de ácidos imido-alcanpercarboxìlicos
CN203524844U (zh) 急救用眼角膜异物镜
AR036018A1 (es) Proceso para aislar monohidrato de imipenem cristalino puro
ES2183522T3 (es) Cristalizacion de lactitol, producto de lactitol cristalino y utilizacion del mismo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure